欢迎您访问中乔新舟官网!400-038-9959我的购物车(0)
您当前的位置:首页 > 产品中心
BHT101人甲状腺癌细胞(STR鉴定)
英文名:BHT101
货号:ZQ0312
价格:¥1800.00
加入购物车,提交订单信息之后,我们会第一时间与您取得联系!
推荐组合

BHT101人甲状腺癌细胞(STR鉴定)

¥1800.00
+

BHT-101人甲状腺癌细胞专用培养基

¥650.00

配套完培,省时省力,单买细胞无优惠

=

细胞套餐惊爆价

¥2450
加入购物车
  • 产品说明
  • 产品规格
  • 参考文献
  • STR鉴定

产品名称

BHT101人甲状腺癌细胞

货号

ZQ0312

产品介绍

BHT101 细胞系源自一名 63 岁女性的淋巴结转移,该女性被诊断为间变性乳头状甲状腺癌。该细胞系由一种高度侵袭性和致命性的甲状腺癌建立,这种癌症以进展迅速和预后不良而闻名。BHT101 细胞以缺乏激素产生而著称,这对于源自间变性甲状腺癌的细胞来说是典型的,因为这些细胞通常失去合成甲状腺激素的能力,而甲状腺激素是分化程度更高的甲状腺组织的特征。

就生物标志物表达而言,BHT101 细胞对甲状腺球蛋白和甲状腺素 (T4) 部分呈阳性。甲状腺球蛋白是一种前体糖蛋白,对甲状腺激素 T3 和 T4 的产生至关重要,常用作区分甲状腺癌类型的肿瘤标志物。 BHT101 细胞中存在甲状腺球蛋白,即使只是部分存在,对于研究甲状腺癌病理学和甲状腺癌分化的分子机制也具有重要意义。该细胞系的独特特征使其成为研究未分化甲状腺癌进展和转移行为的宝贵模型,有助于深入了解驱动这些过程的分子改变。

种属

性别/年龄

女/63岁

组织

甲状腺;来自转移灶:淋巴结

疾病

甲状腺癌

细胞类型

肿瘤细胞 

形态学

上皮样细胞

生长方式

贴壁

倍增时间

大约24~72小时 

培养基和添加剂

DMEM高糖(品牌:中乔新舟 货号:ZQ-100+20%胎牛血清(中乔新舟  货号:ZQ500-A)+1%P/S(中乔新舟  货号:CSP006

推荐完全培养基货号

ZM0312

生物安全等级

BSL-1

STR位点信息

Amelogenin:X
CSF1PO: 12 (DSMZ=ACC-279)
:12,13 (Cosmic-CLP=906696; PubMed=30737244)
D2S1338:20,23
D3S1358:16,17
D5S818: 10,11
D7S820: 10,11
D8S1179:13,14,15 (PubMed=18713817; PubMed=30737244)
:15 (DSMZ=ACC-279)
D13S317:12
D16S539:9,11
D18S51: 12,15
D19S433:13,15
D21S11: 29,32.2
FGA:18,24
Penta D: 9
Penta E:10,17
TH01 9,9.3
TPOX:8
vWA:18,19 (PubMed=18713817)
:19 (Cosmic-CLP=906696; DSMZ=ACC-279; PubMed=30737244)

培养条件

95%空气,5%二氧化碳;37℃

抗原表达/受体表达

*** 

基因表达

*** 

保藏机构

DSMZ; ACC-279

供应限制

仅供科研使用

货号

ZQ0312

发货规格

活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一

发货形式

活细胞:常温运输;冻存管:干冰运输

储存温度

活细胞:培养箱;冻存管:液氮罐

产地

中国

供应限制

仅供科研使用


PubMed=8099464; DOI=10.1007/BF02899271
Palyi I., Peter I., Daubner D., Vincze B., Lorincz I.
Establishment, characterization and drug sensitivity of a new anaplastic thyroid carcinoma cell line (BHT-101).
Virchows Arch. B. Cell. Pathol. Incl. Mol. Pathol. 63:263-269(1993)


PubMed=18713817; DOI=10.1210/jc.2008-1102
Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. III, Smallridge R.C., Haugen B.R.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
J. Clin. Endocrinol. Metab. 93:4331-4341(2008)


PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)


PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)


PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)


PubMed=23833040; DOI=10.1210/jc.2013-2383
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)


PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)


PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953
Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C., Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)


PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)


PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)


PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

公司简介 / Company profile
上海中乔新舟生物科技有限公司
Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd.
           上海中乔新舟生物科技有限公司(官网:www.zqxzbio.com)成立于2011年,历经...
联系我们 / Contact
电 话:021-56760357;021-56760351
传 真:
邮 箱:sales@zqxzbio.com
邮 编:200439
地 址:上海市宝山区长江南路180号
Copyright © 2014 ZQXZBIO All rights reserved.
技术支持:中乔新舟沪ICP备14008091号